Baseline clinicopathologic characteristics in patients with PBL
| Characteristic . | PBL group (N = 33) . |
|---|---|
| Age, median (range), y | 61.5 (29-86) |
| Sex | |
| Female | 10 (33.3%) |
| Male | 23 (69.7%) |
| HIV status | |
| HIV-positive | 14 (42.4%) |
| HIV-negative | 19 (57.6%) |
| EBV status | |
| EBV-positive | 20 (60.6%) |
| EBV-negative | 13 (39.4%) |
| HIV- and EBV-positive | 13 (39.4%) |
| R-IPI | |
| 0 | 4 (12.1%) |
| 1-2 | 11 (33.3%) |
| >2 | 18 (54.5%) |
| Stage (Ann Arbor) | |
| I | 6 (18.2%) |
| II | 8 (24.2%) |
| III | 8 (24.2%) |
| IV | 11 (33.3%) |
| B symptoms | |
| Yes | 15 (45.5%) |
| No | 18 (54.5%) |
| Chromosomal aberrations | |
| MYC overall | 26 (78.8%) |
| MYC amplification | 12 (36.4%) |
| MYC split (+/− amplification) | 14 (42.4%) |
| CD30 by immunohistochemistry | |
| Positive | 7 (21.2%) |
| Negative | 26 (78.8%) |
| Extranodal sites | |
| 0 | 4 (12.1%) |
| 1-2 | 27 (81.8%) |
| >2 | 2 (6.1%) |
| ECOG performance status | |
| 0-2 | 25 (75.8%) |
| >2 | 8 (24.2%) |
| Lactate dehydrogenase | |
| Normal | 10 (30.3%) |
| Elevated | 23 (69.7%) |
| CNS involvement at diagnosis | |
| Yes | 0 (0.0%) |
| No | 33 (100.0%) |
| Front-line therapy regimen | |
| CHOP-like | 21 (63.6%) |
| R-based | 5 (15.2%) |
| Others* | 8 (24.2%) |
| Refusal of treatment | 2 (6.1%) |
| Front-line therapy response rates (n = 32) | |
| CR | 10 (30.3%) |
| VGPR | 4 (12.1%) |
| PR | 5 (15.2%) |
| SD | 5 (15.2%) |
| PD | 7 (21.2%) |
| Characteristic . | PBL group (N = 33) . |
|---|---|
| Age, median (range), y | 61.5 (29-86) |
| Sex | |
| Female | 10 (33.3%) |
| Male | 23 (69.7%) |
| HIV status | |
| HIV-positive | 14 (42.4%) |
| HIV-negative | 19 (57.6%) |
| EBV status | |
| EBV-positive | 20 (60.6%) |
| EBV-negative | 13 (39.4%) |
| HIV- and EBV-positive | 13 (39.4%) |
| R-IPI | |
| 0 | 4 (12.1%) |
| 1-2 | 11 (33.3%) |
| >2 | 18 (54.5%) |
| Stage (Ann Arbor) | |
| I | 6 (18.2%) |
| II | 8 (24.2%) |
| III | 8 (24.2%) |
| IV | 11 (33.3%) |
| B symptoms | |
| Yes | 15 (45.5%) |
| No | 18 (54.5%) |
| Chromosomal aberrations | |
| MYC overall | 26 (78.8%) |
| MYC amplification | 12 (36.4%) |
| MYC split (+/− amplification) | 14 (42.4%) |
| CD30 by immunohistochemistry | |
| Positive | 7 (21.2%) |
| Negative | 26 (78.8%) |
| Extranodal sites | |
| 0 | 4 (12.1%) |
| 1-2 | 27 (81.8%) |
| >2 | 2 (6.1%) |
| ECOG performance status | |
| 0-2 | 25 (75.8%) |
| >2 | 8 (24.2%) |
| Lactate dehydrogenase | |
| Normal | 10 (30.3%) |
| Elevated | 23 (69.7%) |
| CNS involvement at diagnosis | |
| Yes | 0 (0.0%) |
| No | 33 (100.0%) |
| Front-line therapy regimen | |
| CHOP-like | 21 (63.6%) |
| R-based | 5 (15.2%) |
| Others* | 8 (24.2%) |
| Refusal of treatment | 2 (6.1%) |
| Front-line therapy response rates (n = 32) | |
| CR | 10 (30.3%) |
| VGPR | 4 (12.1%) |
| PR | 5 (15.2%) |
| SD | 5 (15.2%) |
| PD | 7 (21.2%) |
CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; CNS, central nervous system; CR, complete response; ECOG, Eastern Cooperative Oncology Group; GCB, germinal-center B-cell like; PD, progressive disease; PR, partial remission; R, rituximab; R-IPI, revised-international prognostic index; SD, stable disease; VGPR, very good partial remission.
Indicates other regimen (eg, bendamustine) or palliative cytoreductive treatment.